Drug Trial Radar · NCT07213765
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Jul 24, 2025
Primary completion
Sep 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Bin CaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MicuRx; Shanghai Pulmonary Hospital, Shanghai, China; Beijing Chest Hospital; Anhui Chest Hospital; Jiangxi Chest Hospital; Guangzhou Chest Hospital.; Weifang Second People's Hospital; Shandong Public Health Clinical Center; Changsha Central Hospital
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen decrease the bacterial load, lesion severity and improve the life quality of patients with mycobacterium avium pulmonary disease? What medical problems do participants have when taking contezolid for an extended length? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further decrease the bacterial load, lesion severity and improve the life quality of patients with mycobacterium avium pulmonary disease? Participants will: Take contezolid and standard regimen (azithromycin, ethambutol, and rifampicin) for 6 months, contezolid is administered every day while other drugs are taken three times a week OR take standard regimen three times a week for 12 months. Visit the clinic once every 1 month for checkups and tests.
Conditions
- Mycobacterium Avium Complex Pulmonary Disease
Interventions
ContezolidDrug
contezolid 800mg po q12h\*6m
AzithromycinDrug
azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*6m
AzithromycinDrug
azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*12m
Ethambutol (E)Drug
ethambutol 25mg/kg po tiw\*6m
Ethambutol (E)Drug
ethambutol 25mg/kg po tiw\*12m
Rifampicin (R)Drug
rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*6m
Rifampicin (R)Drug
rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*12m
Primary outcomes
What the sponsor says the trial is designed to measure.
- culture conversionTime frame: end of month 6
- CT lesion absorptionTime frame: end of month 6
- QOL-B+NTM moduleTime frame: end of month 6
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Anhui Chest Hospital
Hefei, Anhui, China · Recruiting
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Guangzhou Chest Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Jiangxi Chest Hospital
Nanchang, Jiangxi, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.